Diverse presentations of cutaneous mosaicism occur in CYLD cutaneous syndrome and may result in parent-to-child transmission - 09/11/19
Abstract |
Background |
Clusters of rare cylindroma or spiradenoma tumors are a recurrent clinical presentation, yet conventional genetic testing results in individuals with these tumors are frequently normal.
Objective |
To determine if genetic mosaicism accounts for such cases.
Methods |
A study of 6 cases from a series of 55 patients who met criteria for diagnostic gene testing for pathogenic CYLD variants over a 5-year period (2012-2017) was performed. A novel genetic assay was used to study DNA from peripheral blood leukocytes and, where possible, matched skin and tumor tissue.
Results |
Two patients had mosaic pathogenic CYLD variants in both the blood and skin. One of these patients transmitted a pathogenic variant to her daughter, and we report the novel phenotype of a contiguous gene deletion syndrome involving CYLD. Two patients had recurrent pathogenic variants in skin tumors from a single cluster but none detectable in the blood.
Limitations |
The remaining 2 patients had clinical features of mosaicism, but these cases were not solved with the assays used because of a lack of access of fresh tumor tissue.
Conclusion |
Genetic mosaicism should be considered in patients presenting with clustered cylindromas, because this may inform genetic testing and counseling of these patients.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : Brooke-Spiegler syndrome, CYLD, CYLD cutaneous syndrome, genetic counseling, genetic testing of the skin, mosaicism, parent-to-child transmission
Abbreviations used : CCS, LOH, Mb, NGS, PCR, PGD, SNP
Plan
| Funding sources: Supported by a Wellcome Trust–funded Intermediate Clinical Fellowship (WT097163MA) (Neil Rajan), the Barbour Foundation (Majid Arefi), and the Newcastle NIHR Biomedical Research Centre (Siobhan Muthiah). |
|
| Conflicts of interest: None disclosed. |
|
| These data were presented as poster presentations at the International Investigative Dermatology Meeting, Orlando, Florida, May 2018, and the European Society of Human Genetics, Milan, Italy, June 2018. |
|
| The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the UK Department of Health. |
|
| Reprints not available from the authors. |
Vol 81 - N° 6
P. 1300-1307 - décembre 2019 Retour au numéro
Article précédent
- Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: A cohort study
- Joy Wan, Nandita Mitra, Ole J. Hoffstad, Albert C. Yan, David J. Margolis
- Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review
- Sabrina Popatia, Kelsey S. Flood, Nicole M. Golbari, Parth V. Patel, Suzanne M. Olbricht, Alexa B. Kimball, Martina L. Porter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?